She asked: “If they got all the cancer out, why do I still need radiation?” It should have been easy to explain. Instead, I found myself saying things like “to be safe” and “to reduce recurrence risk” without actually telling her what her risk was without treatment, how much radiation might reduce it, or what that difference meant for her. I was describing what we did, not why it mattered for the person in the room. That question has stayed with me. It is the question that changed how I practice.

The question has changed

For most of my early career, breast radiation meant a fairly predictable course: five days a week, often for five or six weeks, treating the entire breast. The discussion was not nuanced. What I spend time asking now is completely different: How much treatment does this particular woman actually need?

That shift has moved through all of cancer medicine. We are getting better at identifying cancers that carry completely different risks even when they look similar under a microscope and arise in the same place. Breast cancer is not one disease. A small, estrogen-sensitive cancer in a woman in her seventies is biologically and clinically a different problem from an aggressive triple-negative cancer in a woman in her thirties. Tumor size. Lymph-node involvement. Hormone receptors. HER2 status. Age. Systemic treatment. These characteristics change not just how aggressive we need to be, but whether we need to be aggressive at all. The word breast cancer tells us where the disease started. It does not tell us the whole story. As we became better at measuring those differences, my conversations with patients changed too.

What “we got it all” actually means

When a surgeon says the cancer was completely removed, that statement has a specific meaning: the tumor came out with a rim of normal tissue around it, and a pathologist found no cancer cells at the edge. That is excellent news. But it does not mean zero percent chance that an individual cancer cell remains somewhere in the breast. No imaging can find a microscopic cluster. No surgeon can see it during an operation.

That is where radiation comes in. After breast-conserving surgery, radiation substantially reduces the chance that cancer will return in the breast. For generations of women, that combination allowed us to preserve the breast without sacrificing cancer control. But there is another part of the story: not every woman benefits by the same amount.

Some women can consider skipping radiation

This is one of the things that surprises many patients: there are women with breast cancer for whom radiation after lumpectomy may reasonably be omitted. Two landmark trials followed carefully selected older women with favorable, hormone-sensitive breast cancers after lumpectomy. Radiation substantially reduced the chance of local recurrence. Without radiation, roughly 1 in 10 women experienced a local recurrence within 10 years; with radiation, it was closer to 1 in 100. But that large reduction in local recurrence did not translate into longer survival. At 10 years, overall survival was essentially the same whether women received radiation or not.

That creates a very different conversation. Suppose one treatment reduces a woman’s chance of cancer returning in her breast but does not appear to change how long she lives. Is that treatment worth having? There isn’t one answer. One woman may say, “I want to do everything reasonable to minimize the chance this cancer ever comes back.” Another may say, “If my risk is already low, avoiding another treatment matters more to me.” Both can be rational choices. My job is not to tell someone that radiation works. My job is to help her understand how much it is likely to help her.

Less radiation does not necessarily mean worse treatment

The amount of radiation we deliver has changed too. For years, five or six weeks was standard. Then strong evidence showed that shorter courses worked just as well for many patients. Three- to four-week schedules became common. Now some appropriately selected women can complete breast radiation in five treatments. Others may not need the entire breast treated at all. Partial-breast radiation focuses treatment on the region surrounding the original tumor, where recurrence is most likely.

To someone who learned medicine under the assumption that more treatment equals better treatment, this sounds counterintuitive. It shouldn’t. The goal of cancer treatment is not to deliver the maximum amount of therapy a person can tolerate. It is to deliver enough.

A mastectomy doesn’t always eliminate the need for radiation

I hear this question regularly too: “If the whole breast is gone, why would I need radiation?” The logic makes sense. A mastectomy removes almost all breast tissue. For many women with early-stage breast cancer, no radiation is needed afterward.

But a mastectomy does not automatically make the risk of recurrence disappear. Cancer can extend beyond the breast into lymph nodes or surrounding tissues. Certain combinations of tumor size, lymph-node involvement, and other features can leave enough risk that radiation to the chest wall and regional lymph nodes meaningfully reduces the chance of recurrence. This is why two women who both undergo mastectomy may receive completely different recommendations. One may need no radiation. Another may benefit substantially from it. The operation is only part of the story.

The deeper shift

When I started in this field, I spent much of my thinking on how to deliver radiation effectively while protecting the normal tissues around the tumor. That remains enormously important. But somewhere in the middle of my career, another question became equally important to me: How much treatment does this person actually need?

I cannot point to the moment that changed. It happened gradually, through hundreds of conversations with women after treatment. I began paying more attention not only to whether treatment worked, but to what we were asking someone to endure for the benefit we expected it to provide.

And I started asking myself a harder question: Did I know that benefit existed before I recommended treatment? Or did I know it theoretically? There is a difference.

The theoretical position is: radiation prevents recurrence. The specific position is: How likely is this woman’s cancer to return without radiation? How much will treatment lower that risk? What does that difference mean to her? How does she weigh it against the inconvenience, side effects, and risks of treatment? That is a different conversation. It respects her time, her body, and her right to decide how much benefit is enough. I was not having that conversation early enough.

Sometimes the answer to “how much treatment” is more than a patient expected. A woman may undergo a mastectomy and still benefit substantially from radiation. A tiny tumor may have biological characteristics that make more treatment appropriate. But increasingly, the answer can also be less. Less surgery. Less radiation. Fewer treatments. Smaller treatment areas. For some carefully selected women, no radiation at all.

I did not learn this from being a better doctor. I learned it from listening to women describe what treatment actually costs them. That is not retreating from cancer. It is understanding what progress in cancer medicine actually looks like. When I began my career, progress often meant finding ways to treat cancer more aggressively. Thirty-six years later, I think progress sometimes means having enough evidence to know when we don’t have to.

The question I couldn’t answer well early in my career is the one I now spend the most time trying to answer: How much treatment does this particular woman actually need?

Your health deserves the same kind of individual attention. Take my free 3-minute Capacity Checkup to see where sleep, mood, focus, and physical capacity may be asking for more attention.

The post I’ve Treated Breast Cancer for Decades. Here’s What I’ve Learned About Radiation appeared first on Medika Life.

This is the world that reproductive psychiatry tries to fix. It is the branch of medicine that treats mental health problems tied to pregnancy, childbirth, and the months after birth. It covers depression, severe anxiety, panic attacks, obsessive thoughts about the baby’s safety, bipolar disorder, and the rare but severe break from reality called postpartum psychosis.

Roughly one in five pregnant and postpartum women deal with some kind of mental health condition, from anxiety to depression to more severe illness. Yet only about one in four women with postpartum depression symptoms ever gets a diagnosis, and about half of those get no treatment at all.

For years, physicians and hospitals focused mostly on physical dangers like blood loss during birth. Nurses were trained to watch a mother’s blood pressure, bleeding, and vital signs, but not always her mood, sleep, or thoughts. The numbers now tell a different story, and it is not a comfortable one.

A Killer Hiding in Plain Sight

Federal health reviewers looked closely at deaths connected to pregnancy across dozens of states. Mental health conditions, including suicide and drug overdose, caused close to a quarter of those deaths. Suicide alone accounted for nearly a third of the mental health-related deaths in the most recent review.

A separate large study presented to maternal health doctors went even further. It found that homicide and suicide combined were the single leading cause of death among pregnant and postpartum women, ahead of every physical complication doctors traditionally worry about, including bleeding and high blood pressure.

The danger is not shared equally. Black mothers between the ages of eighteen and twenty-four die from violence during pregnancy and the months after birth at nearly four times the national rate. Researchers also found that states with stronger gun laws saw meaningfully fewer of these violent deaths, suggesting that policy choices outside the hospital walls still shape what happens inside it.

Most of these deaths did not have to happen. Review boards that study them in detail found that the overwhelming majority were preventable, with earlier warning, better screening, or faster access to care. That finding sits at the center of why reproductive psychiatry matters. It is not a small corner of medicine. It is a matter of life and death for young families, and it has been treated as an afterthought for far too long.

When the Warning Signs Are Missed

One of the most frightening conditions in this field is postpartum psychosis. It is rare, striking roughly one or two mothers out of every thousand births, but it can move fast and turn deadly within days. A woman can go from mild sleep trouble to hearing voices or believing things that are not true in hours.

Studies show that a meaningful share of mothers with untreated postpartum psychosis will attempt suicide, and a smaller number will harm their child. Physicians and advocates who work in this space are clear about one thing. Postpartum psychosis is a medical emergency, and with fast, proper treatment, most mothers recover fully.

This condition drew national attention when a Massachusetts nurse named Lindsay Clancy went on trial after the deaths of her three young children. Her attorneys argued that severe, untreated postpartum psychosis, not any intent to harm, drove her actions that day. The trial ended without a verdict after jurors could not agree on whether she was criminally responsible. One juror held out in the case. The defense attorney has requested an investigation into his actions.

Physicians who study the condition say cases like hers expose a hard truth. There is no standard screening test for postpartum psychosis, the way there is for postpartum depression, so doctors and family members are often left guessing until symptoms become severe.

Warning signs can include not sleeping for several nights in a row, racing or jumbled thoughts, sudden confusion about what is real, and strange new beliefs about the baby. Legal experts add that courts rarely weigh a mother’s mental state fairly. Only one state currently allows undiagnosed or untreated postpartum psychosis to count in a mother’s favor during sentencing. The gap between what medicine knows about this illness and what the legal system recognizes remains wide. How do you find someone guilty of murder when the research is so limited and faulty, and the treatment is almost pure guesswork?

Confusion at the Pharmacy Counter

Reproductive psychiatry is also fighting a newer problem, public confusion over which medications are actually safe. In September 2025, federal health officials warned that Tylenol use during pregnancy might raise a child’s risk of autism, based on studies that many scientists consider far from settled. In the months that followed, emergency rooms saw pain medication orders for pregnant patients drop by about ten percent, even as new large studies kept finding no clear link between Tylenol and autism.

Antidepressants came under a similar kind of pressure. A federal advisory panel questioned the safety of these drugs during pregnancy, and several panel members claimed, without solid evidence, that the medications cause autism or do not work at all. Leading reproductive psychiatrists pushed back hard.

One new study tracked thousands of patients who had been taking antidepressants for depression or anxiety before becoming pregnant. Those who stopped their medication during pregnancy needed emergency mental health care far more often than those who stayed on it. Untreated depression on its own raises the risk of early birth and dangerous high blood pressure during pregnancy. Doctors in the field say there is no convincing evidence that antidepressants cause autism or birth defects.

This kind of public confusion often pushes women toward the riskier choice, going without needed treatment, out of fear of a smaller and far less certain risk. On top of the confusion, there simply aren’t enough specialists. It’s the same in geriatrics, where few specialists are available.

Many towns and even entire regions have no reproductive psychiatrist at all. To close that gap, hospitals and universities have started programs that let a family doctor or an obstetrician call a psychiatric expert for guidance on the spot, rather than sending every patient to a specialist who might be hours away. These access programs are growing, but they still reach only a fraction of the mothers who need them.

Reproductive psychiatry sits at a hard crossroads. The evidence is clear that mental health, not bleeding or high blood pressure, is now the greatest threat to mothers in the weeks surrounding childbirth. Yet screening tools remain incomplete, public trust has been shaken by conflicting claims from officials, and specialists are spread thin across a country where many families live far from real help.

The good news is that nearly everything described here responds to treatment. Depression and anxiety improve with therapy and medication. Even postpartum psychosis, as frightening as it is, gets better with fast psychiatric care. The real danger is rarely the illness itself. Silence, delay, and bad information often stand between a mother and the help she needs.

Family members often notice first that something is wrong. Physicians in this field give the same advice again and again. Do not wait. Do not assume the feeling will simply pass. And do not let fear over a medication rumor stand between a mother and the treatment that could save her life. A mother’s mental health is not a footnote to her physical recovery from childbirth. It is central to whether she and her baby come through this season of life safely.

The post When Having a Baby Becomes a Mental Health Emergency appeared first on Medika Life.

Women never experience their health that way. Their lives do not fit neatly into funding categories, medical specialties or isolated episodes of care. Health is a continuum that shifts over time, and the market is finally beginning to recognize its size, scientific potential, and human importance.

A new W Group study, “The Road to the Era of Scale,” provides compelling evidence of that shift. Based on the organization’s tracking of more than 500 funding stories and approximately 164 disclosed equity rounds across 15 categories and more than 30 countries, the report found that women’s health companies raised a record $1.55 billion in disclosed equity in 2025, a 41% increase from 2024.

A Market Is Forming, Not Merely Making Headlines

Investment totals can be deceptive. One enormous financing round can make an entire sector appear stronger, deeper, and more expansive than it is in reality. The significance of the W Group findings is that the capital did not simply increase. It spread over the continuum of women’s health.

Eighty-five women’s health companies raised equity in 2025, the highest annual number in the report’s data. Ten rounds reached at least $50 million, twice as many as in 2024, and the average disclosed round grew 29%, from approximately $13.9 million to $18 million.

Capital also became less concentrated among a few celebrated companies. The three largest rounds represented 39% of disclosed funding in 2024, compared with 32% in 2025. Funding received by companies outside the top three grew by 56%, a potential signal that investors are beginning to support a broader range of clinical needs, technologies and business models.

This is what the development of an investment ecosystem looks like. Capital begins to flow beyond the familiar names and into diagnostics, therapeutics, clinical infrastructure and care models that address different stages of a woman’s life.

Oncology received the largest share of investment, with the report estimating more than $600 million across at least 12 rounds. Fertility and assisted reproductive technology attracted more than $230 million, while maternal health drew approximately $160 million. Menopause, sexual and reproductive health, hormone diagnostics and pelvic health also received new support.

Endometriosis offers a particularly important example. Long dismissed, misunderstood and frequently diagnosed only after years of pain, the condition attracted more than $56 million across five rounds in 2025. The investments spanned therapeutics, diagnostics, and imaging, suggesting that the market is beginning to view endometriosis as a complex clinical challenge requiring multiple forms of innovation.

The same shift can be seen in metabolic health. SheMed’s $50 million Series A helped establish women-specific GLP-1 care as an investable category, reflecting the growing recognition that medicines, monitoring and health interventions must account for biological differences rather than treating the male body as the universal clinical norm.

The Women’s Health Innovation Map Is Becoming Global

The United States remains the dominant destination for women’s health capital, but the sector is no longer exclusively an American story. The US ecosystem also benefits from Organon, one of the few global pharmaceutical companies built around women’s health, whose portfolio, partnerships and commercial reach can help promising science cross the difficult divide between startup innovation and patient access.

Beyond the United States, the report found a broader geographic footprint in 2025, with companies and investors across Europe, Israel, India, Canada and the Middle East contributing to the market’s development.

The UK was the most active non-US ecosystem by company count in the W Group data. British companies were represented across metabolic health, endometriosis, hormone diagnostics, menstrual health, maternal care and other categories.

That entrepreneurial activity is now being matched by policy attention. England published a renewed 10-year Women’s Health Strategy in April 2026, aligned with the country’s broader health plan and centered on giving women greater voice, choice and power in decisions about their care. The government has also outlined efforts to streamline gynecologic care, improve access for conditions such as endometriosis and fibroids and confront inadequate approaches to women’s pain.

This matters because innovation cannot succeed through capital alone. A company may develop a better diagnostic or care platform. Still, its impact will remain limited unless clinicians trust it, health systems can adopt it, reimbursement supports it and patients can reach it. That is the difference between invention and innovation.

France is building another part of that infrastructure. The Île-de-France region has created FemTech Île-de-France, an investment fund targeting €50 million for women’s health innovation, supported by the scientific expertise of Université Paris Cité. Regional plans also include a specialized incubator effort and an interdisciplinary institute that connects research, clinical education, and innovation.

The French initiative is notable because it does not treat funding as an isolated intervention. It attempts to link capital with scientific expertise, company development and a regional health innovation strategy. That combination can help promising startups move beyond an initial idea and toward evidence, regulatory progress and clinical adoption.

France’s women’s health momentum is also reflected in Lyon-based Ziwig Biotech, whose Endotest uses salivary RNA analysis and artificial intelligence to provide a noninvasive diagnostic test for endometriosis, demonstrating how French biotechnology can turn a condition long marked by diagnostic delay into a precision-medicine opportunity.

Israel contributes another important dimension. Its health innovation culture is built upon deep scientific expertise, sophisticated health data, globally connected medical centers and an instinct for solving difficult clinical problems. In 2025, Israel presented a delegation of women’s health innovators at Expo 2025 Osaka, bringing companies and health leaders together with counterparts from Japan, the United States and Mexico.

Israel’s strength in technology, however, coexists with a persistent capital and leadership gap for women. An Israel Innovation Authority report found that women remain approximately one-third of the country’s high-tech workforce, while holding only 17% of senior management positions and 10% of startup CEO roles. The number of women working in research and development has risen sharply, but their representation in entrepreneurship, leadership and investment remains disproportionately low.

That disparity should concern anyone interested in women’s health innovation. When women are missing from the rooms where companies are founded, clinical priorities are established and capital is allocated, unmet needs are more likely to remain unseen.

The opportunity in Israel has two paths to consider. The country can export women’s health technologies to global markets while also ensuring that more women participate as founders, scientific leaders, investors and decision-makers shaping those innovations.

The Most Dangerous Gap Sits in the Middle

The report’s most urgent finding is not the record amount invested. It is the continuing Series A bottleneck.

Approximately 35-40 women’s health companies raised seed or pre-seed capital in each of the two years studied. Only about 20 to 25 reached Series A, and many companies that appeared at the seed stage in 2024 did not return with a Series A round in 2025.

Seed funding can demonstrate that a concept is interesting. Series A funding is often the stage at which a company must demonstrate that the concept can become clinically credible, commercially sustainable, and capable of operating within a complex health system.

This stage requires companies to generate evidence, recruit specialized talent, navigate regulation, protect sensitive patient information and establish a credible path to payment. It is also where founders discover that a technically elegant solution may not fit naturally into clinical workflows or address the daily realities faced by patients and health professionals.

The loss of promising companies at this stage is not only a financial concern. A stalled financing round can mean that an earlier diagnostic never reaches a physician, a new treatment never enters a clinical trial or a more humane care model never reaches the people who need it.

Specialist funds can help bridge that gap, and the report identified at least 11 new investment vehicles launched in 2025 with a women’s health mandate. Pharmaceutical companies and major generalist venture firms are also beginning to participate, an important sign that the sector is moving beyond support from a small circle of committed specialists.

The transition remains incomplete. Women’s health will not achieve sustained growth until generalist investors consider it a standard component of health investing rather than a special theme to be visited only occasionally.

Capital Still Follows Visibility More Than Burden

The funding pattern also reveals an uncomfortable truth. Conditions receiving the most investment are not always those creating the greatest health burden.

The report estimates that women-specific cardiovascular innovation received only about $2 million in dedicated equity during 2025. Dedicated investment addressing the women-specific dimensions of autoimmune disease was effectively absent, even though women account for the great majority of people living with autoimmune conditions. Mental health and pelvic health also remained dramatically underfunded in relation to their effects on people’s lives.

This does not diminish the importance of investment in fertility, oncology, menopause or maternal health. It does show that markets often follow categories that are easier to describe, sell or recognize before addressing conditions that are scientifically complex, poorly diagnosed or fragmented across medical specialties.

Cardiovascular disease in women is not a niche concern. Autoimmune disease is not a specialty-market curiosity. These are major health challenges that demand gender-specific research, earlier diagnosis, appropriate clinical evidence and investors prepared to build a long-term thesis.

Five years ago, menopause appeared similarly overlooked. Greater visibility, advocacy and scientific attention helped change investor understanding. Cardiovascular, autoimmune, and mental health innovation now requires a comparable shift.

Scale Must Mean Better Health Access, Not Only Larger Rounds

Investment is essential, but capital is not the same as care. A successful financing announcement does not reduce the years a woman may wait for an endometriosis diagnosis, reduce the risk of maternal complications or ensure that a new technology reaches people regardless of income or geography.

The true value of capital lies in what it enables people to create. It can help researchers produce evidence, enable founders to recruit skilled R&D teams and give companies time to earn the confidence of regulators, health professionals, payers and patients.

Technology should simplify care rather than introduce another point of friction. Data should help clinicians understand women more fully rather than reproduce historical bias. Artificial intelligence, or its application, should enhance human judgment, not serve as an excuse for health professionals to distance themselves from the people they serve.

The women’s health sector no longer needs to prove that unmet need exists. The record of delayed diagnoses, inadequate research, and dismissed symptoms has been established many times over.

It also no longer needs to prove that successful companies can be created. The expansion of investment across more categories, countries and later-stage rounds shows that women’s health can produce significant scientific advances and scalable enterprises.

The question now is whether investors, policymakers and health systems will support those companies through the winding journey from possibility to practice. That will require patient capital, stronger evidence, workable reimbursement pathways, and a willingness to design care around women’s lives rather than forcing women to navigate systems not designed with them in mind.

The W Group Era of Scale analysis should not be measured only by how much capital enters women’s health. It should be measured by whether that investment leads to earlier diagnoses, better treatments, broader access and less suffering. The true measure of scale will not be dollars invested, but lives improved.

The post Women’s Health Has Entered the Era of Scale. Now Capital Must Catch Up With Care appeared first on Medika Life.

Despite living longer than men, women spend approximately 25 percent more of their lives in poor health, according to research from the World Economic Forum and the McKinsey Health Institute. Across reproduction, brain health, autoimmune conditions, cardiovascular disease, and mental health, the gaps in research, funding, and care are persistent.

That reality provided important context for the launch of The Shift, a new mini documentary series from BBC StoryWorks Commercial Productions, unveiled at HLTH Europe. The series explores issues ranging from reproductive health and cardiovascular disease to autoimmune disorders, menopause, mental health and healthy aging. Through storytelling, the documentary project elevates the experiences of women while highlighting the challenges that persist and the opportunities for progress.

The HLTH EU panel discussion was timed for the opening of The Shift and featured Shahnoor Abbas, Senior Series Developer and Research Development Lead for The Shift at BBC StoryWorks Commercial Productions; Elena Bonfiglioli, General Manager, Global Health & Life Sciences at Microsoft, and Priya Agrawal, MD, Vice President, Global Health Equity and Partnerships at MSD. Their conversation, moderated by Jody Tropeano Greene, Head of Content for HLTH, explored why women’s health remains one of the most significant opportunities for innovation, investment and system improvement.

A Conversation Decades in the Making

The panelists approached the topic from different perspectives, yet a common theme emerged. Women’s health has received increasing attention for more than a decade, but many of the barriers women encounter remain rooted in the design of health systems.

For BBC StoryWorks, The Shift represents an effort to sustain attention on issues that too often receive episodic interest. The series combines personal stories with broader insights into the realities women face across different countries, cultures and stages of life.

The BBC initiative and the HLTH EU mainstage conversation arrive at a time when women’s health is attracting growing attention from investors, entrepreneurs, policymakers and health industry leaders. New companies are emerging. New technologies are being developed. More organizations are recognizing both the societal and economic importance of addressing longstanding gaps in care.

The timing of The Shift is notable. Women’s health innovation is receiving growing attention from investors, entrepreneurs, policymakers and health leaders. Industry analysts estimate that approximately $2 billion was invested in venture-backed women’s health companies across the United States and Europe in 2025, reflecting increased interest in addressing challenges that extend beyond reproductive health to include cardiovascular disease, menopause, mental health, oncology and healthy aging.

The trend signals growing recognition that improving women’s health is a societal imperative and a significant economic opportunity. Yet as the discussion at HLTH Europe made clear, investment and innovation alone will not be enough if women continue to face fragmented systems that are difficult to navigate.

When Access Exists but Navigation Fails

Dr. Agrawal, an obstetrician-gynecologist by training, whose work has included clinical practice in the UK NHS, global pharma brand stewardship in emerging middle-income nations, maternal health awareness initiatives, and the creation of sustainable health markets, described a reality familiar to many women. Access to care may exist on paper; however, reaching that care, understanding available options and navigating fragmented systems remains a challenge.

“We’ve built systems like mazes with different entry points, different providers and different messages,” said Dr. Agrawal. “Women are often left navigating all of this themselves at the moments where they are most vulnerable.”

Her observation echoed the comments by fellow panelists, which touched on an issue that extends beyond women’s health. Across many countries, patients frequently encounter disconnected providers, inconsistent communication and care journeys that require them to coordinate appointments, referrals and information on their own. The burden of connecting those pieces often falls on the individual seeking care rather than the system intended to support them.

For women, that complexity can be especially challenging. Responsibilities related to caregiving, work, family and personal health often intersect at the very moment care is needed. Understanding what symptoms are normal, knowing when to seek help, determining where to go and finding trusted sources of information become added obstacles.

That reality led to one of the discussion’s compelling observations. “This is not an access problem. It’s a design problem.”

The distinction matters. Discussions about women’s health often focus on whether services exist. Design asks a different question: can people realistically find, understand and benefit from those services when they need them most?

The Power of Stories to Sustain Change

The panel also explored the role technology may play in addressing those challenges. Rather than adding new layers of complexity, emerging digital tools and artificial intelligence applications are increasingly being developed to simplify navigation, improve continuity and support people between clinical encounters.

“What excites me is that technology is finally starting to reduce friction instead of adding layers of complexity,” Dr. Agrawal observed.

That perspective aligned with comments from Bonfiglioli, whose work at Microsoft focuses on helping health systems leverage data, cloud technologies and artificial intelligence to improve outcomes. Technology, however, was not presented as a solution on its own. The discussion repeatedly returned to the importance of human connection.

Those themes are central to the documentary series itself. BBC StoryWorks has built a reputation for transforming complex issues into compelling narratives that audiences can understand and relate to. Through The Shift, the goal is not merely to document challenges but to foster greater understanding of the experiences women face and the opportunities that exist to improve care.

Abbas emphasized the power of storytelling to connect data and lived experience. Statistics can identify a problem. Research can explain it. Stories help people understand why it matters and why action is necessary.

That may be the enduring value of The Shift. The series does not introduce a new conversation. Instead, it brings fresh perspectives to longstanding challenges. Through stories from around the world, the films remind viewers that behind every statistic is a person navigating the complexities of health and care. By fostering greater understanding and empathy, the series encourages health leaders, innovators and policymakers to view women’s health not as a periodic topic of interest, but as an ongoing priority deserving sustained attention and action.

The women featured throughout the series deserve more. The discussion at HLTH Europe reinforces that improving women’s health is more than developing new technologies and expanding services. It is also about creating systems that are easier to navigate, more responsive to people’s medical priorities and ultimately more human in their design.

The post At HLTH Europe, BBC StoryWorks Shines a Light on Women’s Health and the Challenge of Navigating Care appeared first on Medika Life.

Listening to the presentations and engaging with researchers, scientists, and patients raised an important question: how do we communicate findings and data in ways that advance patient care while also fostering trust and meaningful relationships between industry and community?

No one-size-fits-all digital solution

Some of the most recent developments in data and research presented in San Antonio are worth recognizing, not only for what they found, but also for what they can teach us. For example, the YES (Young, Empowered & Strong) study demonstrated the potential of a mobile health (mHealth) app to address quality of life issues and reduce key symptoms in young breast cancer survivors.

While the study presented promising information for this group of patients, it also highlighted some persistent challenges, indicating that there is no one-size-fits-all digital solution. First, it highlighted the continued existence of a digital divide, indicating that equitable patient access to digital devices cannot be assumed. The YES study also pointed out valuably that while improvements were seen in some areas of treatment as a result of mobile technology use, several menopausal and psychological challenges for patients remained that were not significantly addressed.

More information is needed

Data from the oral SERD study are exciting. The study validates the oral SERD (Selective Estrogen Receptor Degrader) approach and sets the stage for further development of novel SERDs and combination strategies. This represents a potentially transformative advance in endocrine therapy for HR+ HER2‑breast cancer. While the study’s findings are promising, longer follow-up, survival data, and subgroup analyses are still needed. In addition, data from a hormone therapy in BRCA1/2 carriers study suggest that while hormone therapy may not increase breast cancer risk, treatment remains highly individualized and requires personalized care and shared decision-making to be as effective as possible.

The Cleveland Clinic’s early triple-negative breast cancer (TNBC) vaccine trials showed promising immune responses and good safety in small studies. These preliminary results are promising, but larger trials are necessary to confirm any real clinical benefit.

Finally, the results of a study on neoadjuvant strategies with radiation + Keytruda showed promise in shrinking tumors and boosting immune responses before surgery. These findings challenge the traditional surgery-first paradigm and further support more personalized care. But these approaches remain early and complex, and are not yet standard.

Wellness doesn’t have to be complicated

While early-phase, the results of trials on acupuncture and integrative therapies suggest that these approaches may help survivors with cognitive symptoms (“chemo‑brain”) and improve their quality of life with minimal side effects. These studies highlight that integrative care can complement, not compete with, conventional treatment.

The broader adoption of these approaches will require clinicians to be aware of, sensitive to, and supportive of personalized wellness. Like with other therapies, there’s no one-size-fits-all approach, but these promising findings remind us that wellness doesn’t have to be complicated, overwhelming or inaccessible.

How do we better communicate scientific updates?

The researchers, scientists, funders, and patients who participate in these studies are critical to advancing care and creating a healthier tomorrow. I’m honored to be part of this ecosystem.

This year’s symposium has also prompted me to reflect: How do we best communicate, rather than commercialize, scientific updates? How can we inform, not inflate? How do we continue to educate without exaggerating? What will allow us to better inspire, not deflate?

While thousands of abstracts are presented each year, only a small fraction ultimately changes clinical practice. So, what can we do to ensure they receive a broader hearing?  I believe that as researchers, scientists, and physicians who rely on communicating the promise and potential of our work and its ability to improve patients’ lives, we should follow these four communication imperatives.

• Prioritize the heart of the story, not the headlines. Headline-first news stories are the norm for those consuming news. While the temptation may be to present your work in the best possible light, including caveats (“early stage,” “with limitations”) that accurately convey the current state of a study or research program can help curb misinformation and limit premature hype.

• Encourage dialogue. It’s crucial to establish connections with disease communities to foster collaborative partnerships that facilitate improved communication and outcomes. Intentionally creating channels for questions or feedback on published studies fosters transparency between the industry and the community.

• Non-updates are still updates. Patients who are waiting for effective treatments rely on honest and open communication to base their decisions on. However, it’s essential to recognize that both positive and negative findings contribute to innovation. Breaking down wins and losses in clear language helps bridge the trust gap between the industry and the community.

• Support for replication and wellness research. Currently, there is no large, dedicated Federal program funding large-scale repeat clinical trials solely for confirmation purposes. Greater investment in replicating research in prevention, while advancing breakthrough therapies, could help actualize a whole-person health approach.

The proceedings of SABCS 2025 and the research presented remind us that progress in cancer treatment and care is iterative, collaborative, and deeply human. They also emphasized that, even as we celebrate exciting breakthroughs, we must recognize that honestly communicating the nuances and limitations of research is also our responsibility. As communicators, that is how we translate the most promising research into meaningful, equitable patient care.

The post Promise, Progress and Perspective: Key Takeaways from SABCS 2025 appeared first on Medika Life.

The FemTech Foundation—and Fault Lines

In 2015, fewer than 300 ventures focused on women’s health existed. That number has tripled to 942, according to the Galen Growth HealthTech Alpha™ platform. These ventures now span the female health continuum—gynecology, menopause, oncology, cardiovascular disease, mental health and beyond.

Yet the investment tide has not fully turned in FemTech’s favor. While partnerships have risen 15.3-fold during the past decade, capital deployment has grown only 1.4 times. Compare that to the 2.6x expansion of digital health investments. In 2024, FemTech secured $2.2 billion in funding, a sliver of the $26 billion digital-health pie.

This disparity isn’t due to a lack of innovation—quite the opposite. The problem is systemic: funding gaps, policy voids, and clinical blind spots that overlook the $360 billion “ghost market” of women’s health. That phrase— “ghost market”—is the report’s haunting term for the opportunities left untouched by current investors and providers alike.

From Fertility to Full Spectrum

One of the report’s most critical takeaways is how much the FemTech category is maturing. Fertility tracking and pregnancy apps put the field on the map. But FemTech today is far more.  It recognizes the vast need for medicine to engage with women’s unique health needs, long unaddressed.

The Galen Growth data shows that while gynecology and oncology account for more than half of all FemTech ventures, menopause, chronic pain, autoimmune conditions, cardiovascular disease and mental health are surging into the investment and innovation spotlight. These are not “niche” categories—they represent common, often underdiagnosed or misdiagnosed conditions that disproportionately affect women and impair their quality of life.

This expansion reflects a growing recognition that women’s health is not a subset—it’s a central pillar of public health. As de Salaberry writes in a soon-to-appear Health Tech World byline: “To be transformative, FemTech must address the entirety of the women’s health continuum, including those therapeutic areas that are not traditionally branded as female-specific but affect women in distinct ways.”

Twice the Clinical Evidence—But Still Under Scrutiny

Perhaps the report’s most sobering—and telling—data point is that FemTech ventures generate nearly twice the volume of clinical trials, peer-reviewed research, and regulatory filings as their digital health peers. Twice. That’s not due to past scientific rigor; these companies are held to a higher standard. Founders and advocates must go the extra mile to validate the clinical value of their solutions.

Despite this, systemic barriers remain. The report shows 71 percent of early-stage FemTech ventures struggle to raise a Series A round. Funding the “middle”—those post-seed but pre-scaleup companies—is an urgent priority. Without it, too many promising solutions will stall before reaching the women who need them.

Let’s be clear: this isn’t just about meeting investor milestones. It’s about delivering equity in care. Cardiovascular disease is the leading cause of death among women, yet it remains underrepresented in FemTech portfolios. Alzheimer’s and autoimmune conditions disproportionately affect women, yet receive comparatively little innovation focus.

Those are not oversight gaps. They are deep, systemic failures – disparities in our health innovation system.

From Direct-to-Consumer to Deep Health Integration

Another significant signal of maturity is the shift away from pure direct-to-consumer (DTC) models. In 2024, 42 percent of FemTech partnerships involved health systems, up from just 10 percent in 2020. That’s a tectonic shift from point solutions to systemic integration.

As de Salaberry puts it, “DTC strategies alone cannot reach underserved populations or secure the reimbursement pathways necessary for scale.” Systemic integration—through payers, providers, and public institutions—is essential for sustainability and access. FemTech must live where care happens, not just on consumers’ cell phones.

Regionally, the picture is just as telling, with Europe leading in clinical rigor, with 50 percent of FemTech ventures demonstrating proven clinical strength. North America leads in funding ($1.3B), while Asia-Pacific remains a hub of AI-driven diagnostics, even amid a dip in capital investment. These trends point to what’s next: a future driven by localization, clinical excellence and technology convergence.

Forces Shaping the Future of FemTech

The report outlines five key factors shaping the FemTech evolution during the next five years. They’re worth noting for anyone investing, innovating or advocating for equitable care with an eye toward return on investment:

• Redefining the Scope: FemTech must look beyond reproductive health to address chronic diseases, aging, and behavioral health.
• Breaking the DTC Mold: Success will be defined by integrated partnerships with employers, insurers, and health systems.
• Balancing Rigor and Agility: Regulatory requirements must support innovation without stifling it.
• Funding the Growth Gap: Series A and B support is critical to help early innovators scale.
• Smart Consolidation: M&A isn’t just about exits—it’s about building category leaders with breadth and credibility.

Infrastructure, Not Hype

The key here is infrastructure. FemTech is not a trend—it’s the scaffolding of women’s health innovation. Investors need to hear that message and invest to make this population health category viable.

With nearly half the global workforce made up of women, the ROI on women’s health is not just moral—it’s macroeconomic. The health ecosystem can no longer afford to treat women’s health as an edge case. It is, in fact, the core of population health.

FemTech’s next chapter will be shaped by evidence, equity and integration. It must also be underpinned by trust from payers, providers, and patients. That trust is earned through data, outcomes and the bold assertion that women’s health is health, full stop. This Galen Growth Report goes a long way to demonstrating the positive outcomes when innovation and investment converge.

As Julien de Salaberry wisely states: “The next generation of Femtech isn’t about visibility—it’s about value, integration, and health systems impact.” That’s not just a forecast—it’s a framework for what’s next.

[Editor’s Note: For a deeper dive into the Galen Growth FemTech 2025 report, visit galengrowth.com. The full report and press release, are available now.]

The post Galen Growth FemTech 2.0 Report: Elevating Women’s Health from Niche to Necessity appeared first on Medika Life.

Sometimes it’s a look.

A line.

A moment that lands deeper than diagnosis.

This brief essay is a collection of those moments.

Brief.

Unexpected.

And always real.

“The Healing Power of Touch: A Patient’s Insight”

This week, a patient shared a poignant realization that emerged after years of emotional distance from his wife.

They had grown apart, but recently discovered a shared need: the simple, profound act of touch.

He reflected on how a gentle hug or a reassuring hand on the shoulder seemed to bridge the emotional gap between them.

“I think we’re wired for this,” he mused, referencing hormones like oxytocin that respond to physical affection.

His insight aligns with scientific findings.

Oxytocin, often referred to as the “love hormone,” plays a crucial role in social bonding and emotional connection.

Studies have shown that affectionate touch can increase oxytocin levels, reduce stress, and foster feelings of trust and closeness.

In fact, research indicates that even brief moments of affectionate touch can lead to measurable increases in oxytocin, a hormone that contributes to an improved mood and reduced anxiety.

This finding underscores the biological underpinnings of our need for physical connection.

My patient’s experience serves as a reminder that sometimes, healing in relationships doesn’t require grand gestures — just a touch of understanding, quite literally.

For more reflections on connection at the edge of life, read my essay: What Dying Men Confessed When No One Was Listening.

“The Prostitute’s Pasta”

In oncology, gratitude comes in many forms — thank-you notes, quiet nods, even tears.

But sometimes, it arrives as a steaming pan of pasta.

One of our patients, an older Italian gentleman with a twinkle in his eye and impeccable taste, has taken to feeding the staff.

Not metaphorically — literally.

Lasagna, tiramisu, and even delicate cannoli are dusted with sugar like freshly fallen snow.

Today, he arrived bearing a new dish. “Pasta Puttanesca!” he announced proudly. “You know — the prostitute’s pasta.”

A pause.

Then laughter. Nurses chuckled. My medical assistant nearly dropped her stethoscope.

He winked. “They say it was made quickly, between clients.”

I’ll leave the etymology to linguists.

But I can tell you this: the olives were briny, the sauce was bold, and the gratitude was unmistakable.

This event was something else entirely in a world often defined by scans and side effects.

A recipe for connection.

Served al dente.

Note: For patient privacy, I have modified some details.

Here are my previous Clinic Notes essays:

1. Clinic Notes 5/18/2025
2. Clinic Notes 6/26/2025

Want more stories like these — plus the science behind living longer and better? I’ve distilled the most powerful lessons from oncology, aging research, and patient wisdom into my new ebook: Extending Life and Healthspan.

Practical, evidence-based, and full of humanity.

The post Clinic Notes: What My Patients Said This Week appeared first on Medika Life.

Usually, detecting cancer is done through a combination of physical exams, imaging tests, blood tests, and biopsies. A biopsy, where a tissue sample is taken and examined under a microscope. This process is time-consuming and often relies on parts of the health system working together quickly, which does not always happen. Some cancers, like brain, pancreatic, and ovarian cancers, are difficult to detect, which can slow diagnosis even further.

By contrast, liquid biopsies can detect cancer more quickly. This type of testing looks at bodily fluids (typically blood) for evidence of cancer cells by finding biomarkers that are shed by cancer cells into the bloodstream. Liquid biopsy technology is advancing fast and with new technologies emerging, such as using light to detect these signals. This is a similar approach to that used when small swabs are passed over luggage and analysed at airport security.

By combining this spectral analysis with artificial intelligence (AI), it is possible to speed up cancer detection at a significantly lower cost. At the forefront of this revolution in cancer detection is Dr. Holly J. Butler. Dr Butler is the co-founder and CTO of Dxcover, the company behind the award-winning multiomic spectral analysis platform. Grounded in biophotonics and driven by an unwavering dedication to improving patient outcomes, Dr Butler is striving to bring about a new era of non-invasive diagnostics; one where a couple of drops of blood and a beam of light might one day save millions of lives.

Dr Butler, alongside an award-winning leadership and research team, has been developing methods to analyse blood samples using infrared spectroscopy. What they discovered was a way of ‘reading’ the biochemical fingerprint of disease in a standard blood test. This research became the foundation of an award-winning proprietary platform that leverages a unique combination of AI and spectral analysis to detect patterns in small blood amounts, allowing clinicians to find cancer earlier, more accurately, and far more affordably than many existing techniques.

The potential is enormous. Unlike conventional liquid biopsies, which rely on picking up fragments of tumour DNA, this platform is more wide-ranging in its approach. It uses a multiomic strategy – looking at proteins, lipids, metabolites, and more – through a process known multiomic spectral analysis. It translates to even tiny tumours, sized at just 0.2 cm, being capable of leaving a detectable trace. And it’s all done with just nine microlitres of blood.

Dr Butler’s drive to transform scientific ideas into reality started early. After her Ph.D., she took on a Scottish Enterprise-funded project to translate laboratory-based research into clinical diagnostics. Her entrepreneurial endeavours were making waves as early as 2017 – she was ‘Young Entrepreneur of the Year’ at the Scottish Women’s Awards and received the Women in Innovation award at the Global Game Changers Awards. She has continued to be a vocal advocate for women in STEM and an active mentor to early-career scientists and entrepreneurs via the Strathclyde Inspire network in the intervening period.

“I’ve always been drawn to problems where science can make a real, tangible difference in people’s lives,” she says. “To me, early detection for the most difficult to detect cancers is one of the biggest, most urgent problems we face – and one we hope to solve.”

Dr. Butler’s role in bringing this innovation along is as much practical as it is strategic. She is part of a team that spans lab operations, data, software, quality and regulatory affairs, pushing the science to clear the bars for real-world medical use. “You can’t just invent a technology,” she says. “You need to prove that it works, scale it with safety, meet stringent quality specifications, and prove how it fits into clinical pathways. That is the challenge.”

For Dr Butler, it is about the impact on lives. “Cancer still kills nearly 10 million people a year,” she says. “The difference between early or late detection can be life and death. We want to make early detection routine – not something that’s just for some individuals or comes too late.”

Now pursuing an Executive MBA, Dr. Butler is expanding her leadership credentials. “Science gave me the means to innovate,” she says. “But the MBA is teaching me to lead, to strategise, to build something that can last.”

That ecosystem, she hopes, will be one where innovation and inclusion go hand-in-hand. She’s particularly passionate about ensuring that diagnostic breakthroughs become accessible across communities. “We’re aiming for a future where your GP can run a test like this early—long before you’re even referred to a specialist,” she explains.

Dr. Butler’s work remains patient-centred and personal. “Every time we detect a cancer that would have been missed – that’s the goal,” she says. “And every time we improve the technology is a step closer to a world where fewer people have to hear the words, ‘if only we’d caught it sooner.'”

The post Shining a Light on Early Cancer Detection appeared first on Medika Life.

Many of my patients have recently been asking me what it means to have dense breasts.

They sometimes carry a letter saying that their mammograms showed heterogeneously (or extremely) dense breast tissue.

The U.S. government now mandates that radiologists report breast density on mammogram reports but offers no guidance on how to do so.

In this Breast Cancer Awareness month, I want to provide some information about the implications of having dense breasts.

Breast Density Reporting

Beginning September 10, 2024, the U.S. government mandated this:

“Mammography facilities must provide all patients receiving a mammogram with one of two Federal breast density notification statements (either “not dense” or “dense”).“

Additionally, the mammogram report sent to referring providers must include an assessment of the patient’s breast density.

Defining Breast Density

Dense breasts are a mammographic finding in which the breast tissue appears more glandular or fibrous relative to fatty tissue.

The breast comprises two types of tissue: glandular tissue, which produces milk, and fatty tissue, which provides support and cushioning.

Dense breasts contain more glandular and fibrous tissue and less fatty tissue, which makes them appear denser on a mammogram.

Four Categories of Breast Density

The American College of Radiology classifies breast density into four categories:

1. Almost entirely fatty: The breast comprises fatty tissue and is the easiest to read on a mammogram.
2. Scattered areas of fibroglandular density: Although some areas of glandular and fibrous tissue exist, the breast is still considered primarily fatty.
3. Heterogeneously dense: There are many glandular and fibrous tissue areas, and the breast is considered moderately dense.
4. Extremely dense: This means the breast is very dense, with a lot of glandular and fibrous tissue.

Patient Notifications

A radiologist — a doctor who reads your mammogram — assigns your breasts a density.

As noted above, s/he will place each mammogram into one of the four breast density categories.

Your mammogram report may offer these observations:

• If NOT DENSE: “Breast tissue can be either dense or not dense. Dense tissue makes it harder to find breast cancer on a mammogram and also raises the risk of developing breast cancer. Your breast tissue is not dense. Talk to your healthcare provider about breast density, risks for breast cancer, and your situation.”
• If DENSE: “Breast tissue can be either dense or not dense. Dense tissue makes it harder to find breast cancer on a mammogram and also raises the risk of developing breast cancer. Your breast tissue is dense. In some people with dense tissue, other imaging tests and a mammogram may help find cancers. Talk to your healthcare provider about breast density, risks for breast cancer, and your situation.”

Let’s turn to the implications of breast density.

Breast Density Distribution

The American College of Radiology (ACR) observes the following population distribution of breast density:

About 10 percent have almost entirely fatty breasts. At the other extreme, 10 percent have extremely dense breasts.

Eighty percent fit into one of the middle categories.

What causes dense breast tissue?

It’s unclear why some women have dense breast tissue while others do not. You may be more likely to have dense breasts if you:

• Are younger. Breast tissue often becomes less dense with age.
• Have a lower body mass index. Individuals with less body fat are more likely to have dense breast tissue than women who are obese.
• Take hormone therapy for menopause. Those taking combination hormone therapy to relieve signs and symptoms of menopause are more likely to have dense breasts.

Breast Density Implications

Having dense breasts may increase your chances of getting breast cancer.

Moreover, dense breasts make it more challenging for radiologists (and their artificial intelligence friends) to spot cancer on mammograms.

Unfortunately, dense breast tissue appears white on a mammogram.

Lumps, both cancer and non-cancer, often appear white, too. I often say to my patients that dense breasts make it like you are looking for a snowball in a snowfield.

In summary, dense breasts can raise cancer risk and make mammograms less accurate.

Mammograms Are Still Important

First, while many of my patients with dense breasts initially think that mammograms are useless for them, mammograms are still a part of routine imaging.

After all, mammograms are the only medical imaging screening test proven to reduce breast cancer deaths.

Each week, my radiology team finds cancers on mammograms in women with dense breasts.

What Else Can You Do?

That said, here are some tactics you can use:

• Get digital breast tomosynthesis (DBT or 3-D mammograms). DBT creates breast images in slices from many angles, making abnormalities easier to see. Tomo mammograms increase the number of cancers discovered without other imaging.
• Consider ultrasound and magnetic resonance imaging (MRI). These advanced imaging approaches can help find cancers that a mammogram doesn’t indicate. However, breast MRI and ultrasound show many more findings that aren’t cancer (false positive), resulting in added testing.
• Know your breast cancer risk. We have many calculators (varying in complexity and weighing different factors — including family history).

There is no national standard for following up on dense breast reports.

Screening Recommendations

The American College of Radiology suggests that you talk with your healthcare provider and discuss your breast cancer risk.

Even if you have a low breast cancer risk (and have fatty breasts), you should get annual mammograms beginning at 40.

The U.S. Preventative Task Force recommends that all women get screened for breast cancer every other year, starting at age 40 and continuing through age 74.

The Real Problem

Radiologists must describe breast density on your mammogram report.

However, we don’t know what to do with this information.

For example, the American College of Radiology and the National Comprehensive Cancer Network recommend that women and their doctors consider supplemental screening.

On the other hand, the American College of Obstetricians & Gynecologists and the U.S. Preventive Services Task Force offer there is insufficient evidence of benefit to recommend additional tests.

Additional tests can detect more cancers than mammograms alone. However, we have no evidence that extra testing saves lives.

And This

Some studies raise concerns about the reliability of the system used to label breasts as dense or not dense.

A review article in Annals of Internal Medicine reported that radiologists reclassified up to 19 percent of women into a different breast density category — from dense to non-dense or vice versa — on their subsequent screening mammogram.

For those with dense breasts, we don’t know with certainty what the best practice is at this point.

The post Dense Breasts: The Hidden Risk You Can’t Ignore appeared first on Medika Life.

No overuse in the gym.

No trauma.

Just age.

As I transition into my 60s, I occasionally notice small unpleasant elements.

You may relate: It seems that injuries happen more frequently.

I do not have my historical muscle strength.

A new study provides some insights, revealing what may be behind my physical decline.

The 40s

In my mid-40s, I noticed aging signs.

It wasn’t gradual; I suddenly realized I was in my 40s.

It seemed that I had rapidly aged.

As I transition into my 60s, I am noticing the same phenomenon.

Or was it just my imagination?

Stanford researchers recently provided some answers.

Molecular and Microorganism Changes at 44 and 60

Was I wrong in my perception that I had experienced a moment of rapid aging?

A new Stanford University (USA) study tracked thousands of molecule types in adults aged 25 to 75.

The researchers analyzed blood (and other biological samples) from 108 subjects.

Here is the main takeaway message:

People tend to have two dramatic aging leaps — the first at around 44 and the second at approximately 60.

Aging appears to happen in bursts.

These changes appeared no matter what type of molecules the researchers analyzed.

Chasing Squirrels: Punctuated Equilibrium

My nurse sometimes protects me from getting distracted from the task at hand.

Chasing squirrels, Melissa likes to opine.

Well, I am about to chase a squirrel.

What comes to mind is punctuated equilibrium.

This evolutionary biology theory describes evolution as a series of short, rapid times of change interrupted by prolonged periods of stability.

My Harvard professor, the late Stephen Jay Gould, joined Niles Eldridge to develop this theory of how new species emerge and diversify.

They based their view on fossil record patterns developed by paleontologists.

Changes in the 40s

For those in their 40s, the Stanford researchers discovered significant changes in molecules related to:

• alcohol
• caffeine
• cardiovascular disease
• lipid metabolism
• muscle
• skin

Can’t resist sharing this:

“Aging is an extraordinary process whereby you become the person you always should have been.” — David Bowie.

Could Menopause Be Playing A Role?

My first thought?

The mid-40s aging acceleration among women might be secondary to perimenopausal (the transitional period before menopause) changes.

The researchers thought menopause might be playing a role until the scientists realized that men in their 40s had similar molecular alterations.

Changes in the 60s

For individuals in their 60s, molecular alterations appeared related to:

• caffeine metabolism
• carbohydrate metabolism
• cardiovascular disease
• kidney function
• immune regulation
• muscle
• skin

The Researchers Speculate

The scientists wonder if lifestyle influences the alterations in the 40s and 60s.

For example, folks might consume more alcohol in their 40s, a time of higher stress for many.

Anecdotally, I don’t find alcohol consumption to be higher among my patients in the 40 to 50 age group.

Summary

In conclusion, the rapid changes in our bodies during our 40s and 60s are associated with molecular alterations, affecting various aspects of our health and well-being.

Understanding these changes may help you focus on optimizing your lifestyle, including factors like sleep, diet, physical activity, and relationships.

Actionable Takeaways

The bursts of aging in the 40s and 60s remind this 61-year-old to stay focused on optimizing lifestyle.

I pay attention to:

• Sleep
• Diet
• Physical activity
• Relationships
• Minimizing alcohol
• Not smoking
• Sex

My perception of a sudden onset of age-related disorders (including more muscle achiness after working out) seems grounded in reality: We may experience a sudden onset of age-related changes in our bodies.

We don’t understand the full consequences of these molecular changes, but I now better understand my challenges in gaining lots of muscle.

Could it be that the origin of many diseases — that emerge later in life — is related to molecular changes in our 40s?

What has been your experience?

The post Your Body Ages in Leaps: Stanford’s Surprising Findings at Ages 44 and 60 appeared first on Medika Life.